Efecto del tratamiento con plasma convaleciente sobre biomarcadores sanguíneos de inflamación en pacientes con COVID-19, en el Hospital Municipal de Cotahuma en la gestión 2020, La Paz-Bolivia.
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Rev.Cs.Farm. y Bioq
Abstract
Introducción. Los biomarcadores de inflamación desempeñan un papel crucial en el diagnóstico y seguimiento del tratamiento en pacientes con COVID-19. Esta enfermedad provoca una respuesta inflamatoria inusual que agrava el estado del paciente y da lugar a complicaciones severas. Desde 2020, el tratamiento con plasma convaleciente se ha utilizado como una opción terapéutica para pacientes con COVID-19. La principal ventaja de este tratamiento es la transferencia de anticuerpos específicos contra el virus SARS-CoV-2. Estos anticuerpos neutralizan el virus y reducen la carga viral en el organismo, lo que contribuye a disminuir la gravedad de la enfermedad y acelerar la recuperación del paciente. Objetivo. El estudio evaluó el efecto del tratamiento con plasma convaleciente en pacientes con COVID-19 en el Hospital Municipal Cotahuma en 2020. Se analizó el impacto en los niveles de AST, ALT, LDH, PCR y recuento de leucocitos como biomarcadores de inflamación. Materiales y métodos. Se les hizo análisis a todos los pacientes con COVID-19 para determinar su condición y cómo respondían al tratamiento. Para ello, se determinaron los niveles sanguíneos de los biomarcadores considerados como predictores de inflamación o daño tisular, utilizando métodos cinéticos cuantitativos, con el respectivo control de calidad externo e interno. Resultados. Entre los pacientes graves, la mayoría eran hombres, y el grupo etario de 50 a 59 años presentó el mayor número de contagios. Se observaron diferencias significativas en las enzimas AST y ALT entre los grupos de tratamiento. Hubo una disminución en el recuento de leucocitos y la enzima LDH después de los tratamientos. En relación a la proteína C reactiva, se observaron diferencias significativas después de ambos tratamientos. Conclusiones. Se encontró una diferencia significativa en la PCR entre el plasma convaleciente y otros tratamientos para COVID-19. A pesar de la variabilidad en los volúmenes de plasma administrados, se observó que el tratamiento con plasma redujo los biomarcadores en pacientes con estado de salud moderado a crítico, sugiriendo su posible beneficio. La comparación se realizó para destacar las ventajas del plasma convaleciente.
Introduction. Inflammation biomarkers play a crucial role in the diagnosis and monitoring of treatment in patients with COVID-19. This disease triggers an unusual inflammatory response that worsens the patient's condition and leads to severe complications. Since 2020, convalescent plasma therapy has been used as a therapeutic option for patients with COVID-19. The main advantage of this treatment is the transfer of specific antibodies against the SARS-CoV-2 virus. These antibodies neutralize the virus and reduce the viral load in the body, helping to lessen the severity of the disease and accelerate the patient's recovery Objective. The study evaluated the effect of convalescent plasma treatment on patients with COVID-19 at Cotahuma Municipal Hospital in 2020. The impact on levels of AST, ALT, LDH, CRP, and white blood cell count was analyzed as biomarkers of inflammation. Materials and methods. All patients with COVID-19 underwent analysis to assess the severity of their condition and their response to treatment. Blood levels of biomarkers considered predictors of inflammation or tissue damage were measured using quantitative kinetic methods, with appropriate external and internal quality control. Results. Significant differences were observed in the AST and ALT enzymes between the treatment groups. There was a decrease in leukocyte count and the LDH enzyme following the treatments. Regarding C-reactive protein, significant differences were noted after both treatments. Conclusion. A significant difference in CRP was found between convalescent plasma and other COVID-19 treatments. Despite variability in the volumes of plasma administered, plasma treatment was observed to reduce biomarkers in patients with moderate to critical health status, suggesting potential benefit. The comparison was made to highlight the advantages of convalescent plasma.
Introduction. Inflammation biomarkers play a crucial role in the diagnosis and monitoring of treatment in patients with COVID-19. This disease triggers an unusual inflammatory response that worsens the patient's condition and leads to severe complications. Since 2020, convalescent plasma therapy has been used as a therapeutic option for patients with COVID-19. The main advantage of this treatment is the transfer of specific antibodies against the SARS-CoV-2 virus. These antibodies neutralize the virus and reduce the viral load in the body, helping to lessen the severity of the disease and accelerate the patient's recovery Objective. The study evaluated the effect of convalescent plasma treatment on patients with COVID-19 at Cotahuma Municipal Hospital in 2020. The impact on levels of AST, ALT, LDH, CRP, and white blood cell count was analyzed as biomarkers of inflammation. Materials and methods. All patients with COVID-19 underwent analysis to assess the severity of their condition and their response to treatment. Blood levels of biomarkers considered predictors of inflammation or tissue damage were measured using quantitative kinetic methods, with appropriate external and internal quality control. Results. Significant differences were observed in the AST and ALT enzymes between the treatment groups. There was a decrease in leukocyte count and the LDH enzyme following the treatments. Regarding C-reactive protein, significant differences were noted after both treatments. Conclusion. A significant difference in CRP was found between convalescent plasma and other COVID-19 treatments. Despite variability in the volumes of plasma administered, plasma treatment was observed to reduce biomarkers in patients with moderate to critical health status, suggesting potential benefit. The comparison was made to highlight the advantages of convalescent plasma.
Description
Vol. 12, No. 2